Max Robotics — Global Service Robot Directory + US Certification

About

Kevin Lawlor is a leading figure in functional proteomics and biomarker discovery, best known for pioneering serum peptidome profiling to detect cancer. His landmark 2006 study, cited 178 times, demonstrated that serum peptidome patterns can distinguish metastatic thyroid carcinoma from cancer-free controls, and crucially, that these patterns are unbiased by gender and age—a major step toward robust, non-invasive diagnostics. Lawlor’s key contribution lies in shifting focus from static protein abundance to dynamic enzyme activity. He developed the Sequence-specific Exopeptidase Activity Test (SSEAT), a novel “functional” biomarker discovery platform that tracks genuine protease activities in complex biological matrices, rather than mere surrogates of activity. This work, detailed in his 2007 paper (86 citations), has opened new avenues for real-time monitoring of disease-related enzymatic cascades. He further advanced the field by refining MALDI-TOF mass spectrometry methods for monitoring peptidase activities in complex proteomes (2009). Lawlor’s research bridges fundamental enzymology and clinical translation, offering a powerful toolkit for identifying functional biomarkers that reflect actual pathological processes, with lasting impact on cancer diagnostics and personalized medicine.